Salix plans a tax inversion; Lexicon teams up with JDRF on diabetes PhII;

@FierceBiotech: Trending on FierceDrugDelivery@MIT, MicroCHIPS develop remote-controlled contraceptive with on-off delivery. Story | Follow @FierceBiotech

@JohnCFierce: After a taste of disaster, Reata plans a comeback for bardoxolone - in Ph2 for PAH now after CKD blowup. News | Follow @JohnCFierce

@DamianFierce: Bernstein's Porges: "Wouldn't hold our breath" for any meaningful AS revenue from CELG's apremilast. More | Follow @DamianFierce

@EmilyMFierce: Oops: Smallpox discovered sitting in Maryland storage room. Story via The Washington Post | Follow @EmilyMFierce

> Salix Pharmaceuticals ($SLXP) has engineered a reverse merger with Cosmo Pharmaceuticals that will grant it an Irish domicile, joining the cadre of drugmakers fleeing to the country for its lower tax rate. Article

> JDRF has signed on to help fund Lexicon Pharmaceuticals' ($LXRX) Phase II study of LX4211 in young patients with Type 1 diabetes. The drug is an inhibitor of SGLT1 and SGLT2, designed to lower blood glucose levels by expelling excess sugars through the urine. More

> Mariel Therapeutics is buying some bone protein biologics from medical device giant Stryker ($SYK), assets the company said could become treatments for osteoarthritis, chronic kidney disease and organ fibrosis ailments. Story

Medical Device News

@FierceMedDev: Proteome Sciences, U.K. academics spot 10 Alzheimer's predictive biomarkers in blood. FierceDiagnostics story | Follow @FierceMedDev

@StacyALawrence: Surgeons tout benefits of Google Glass in operating room. More | Follow @StacyALawrence

@VarunSaxena2: Check out our special report on the top 10 highest paid med tech CEOs. | Follow @VarunSaxena2

@MichaelGFierce: MIT, MicroCHIPS develop remote-controlled contraceptive with on-off delivery. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Volatile compounds in fruits influence our perception of taste and smell, could trick us into healthy eating. Wired story | Follow @EmilyWFierce

> India may alter medical device taxation that favors imports. Item

> Zimmer, Biomet hit regulatory speedbump in pending merger. Story

> NeuroMetrix gains on FDA clearance of over-the-counter wearable, chronic pain device. Article

Pharma News

@FiercePharma: Biogen prices new, long-acting hemophilia med with eye on patient-switching. Story via FiercePharmaMarketing | Follow @FiercePharma

@EricPFierce: Health Canada tells GSK to get its vaccine house in order as flu season approaches. More | Follow @EricPFierce

@CarlyHFierce: Report: Cancer immunotherapy market to hit $9B by 2022. Item | Follow @CarlyHFierce

> Actavis cans 190 Forest workers while 6 execs share up to $186M in deal 'awards.' News

> Salix picks up Cosmo's Irish unit for $2.7B and a lower tax bill. News

> EU's third pay-for-delay action nails Servier, Teva, Mylan and others. Article

Drug Delivery News

> Researchers develop new chemo that targets mitochondrial DNA. Report

> Sanofi Pasteur taps CureVac for its RNA vaccine tech. Story

> InSite plans 2015 FDA submission for inflammation eye drop with suspended delivery. News

> Vaginal ring achieves localized, sustained release of anti-HIV drugs. More

> MIT, MicroCHIPS develop remote-controlled contraceptive with on-off delivery. Article

Diagnostics News

> U.K. company readies jump into bustling prenatal Dx market. Article

> NIH gives Kansas City startup $3M to come up with a quicker sepsis Dx test. More

> UC San Diego biomarker discovery could boost brain cancer drug's success rate. Story

> With funding secured, Definiens CEO Heydler talks about hoped-for digital tissue Dx boom. Article

> Proteome Sciences, U.K. academics spot 10 Alzheimer's predictive biomarkers in blood. Report

Pharma Marketing News

> Which big brands will still be bringing in the big bucks in 2020? Report

> Merck reaches doctors in India with online teaching tool. More

> Biogen prices new, long-acting hemophilia med with eye on patient-switching. Article

> Report: Cancer immunotherapy market to hit $9B by 2022. Item

> Is a price war imminent when Sanofi's Lantus patent falls? Story

Suggested Articles

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Vertex is keeping mum on exact details but, as with the rest of its biopharma peers, is seeing trial disruption due to the COVID-19 pandemic.

Companies including Novartis and Pfizer are contributing to the joint response through actions including the sharing of proprietary compounds